IPCA Laboratories Ltd
NSE:IPCALAB

Watchlist Manager
IPCA Laboratories Ltd Logo
IPCA Laboratories Ltd
NSE:IPCALAB
Watchlist
Price: 1 591.35 INR 1.13% Market Closed
Market Cap: 403.7B INR
Have any thoughts about
IPCA Laboratories Ltd?
Write Note

Intrinsic Value

The intrinsic value of one IPCALAB stock under the Base Case scenario is 1 210.96 INR. Compared to the current market price of 1 591.35 INR, IPCA Laboratories Ltd is Overvalued by 24%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IPCALAB Intrinsic Value
1 210.96 INR
Overvaluation 24%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
IPCA Laboratories Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for IPCALAB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about IPCALAB?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
IPCA Laboratories Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about IPCA Laboratories Ltd

Provide an overview of the primary business activities
of IPCA Laboratories Ltd.

What unique competitive advantages
does IPCA Laboratories Ltd hold over its rivals?

What risks and challenges
does IPCA Laboratories Ltd face in the near future?

Has there been any significant insider trading activity
in IPCA Laboratories Ltd recently?

Summarize the latest earnings call
of IPCA Laboratories Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for IPCA Laboratories Ltd.

Provide P/S
for IPCA Laboratories Ltd.

Provide P/E
for IPCA Laboratories Ltd.

Provide P/OCF
for IPCA Laboratories Ltd.

Provide P/FCFE
for IPCA Laboratories Ltd.

Provide P/B
for IPCA Laboratories Ltd.

Provide EV/S
for IPCA Laboratories Ltd.

Provide EV/GP
for IPCA Laboratories Ltd.

Provide EV/EBITDA
for IPCA Laboratories Ltd.

Provide EV/EBIT
for IPCA Laboratories Ltd.

Provide EV/OCF
for IPCA Laboratories Ltd.

Provide EV/FCFF
for IPCA Laboratories Ltd.

Provide EV/IC
for IPCA Laboratories Ltd.

Show me price targets
for IPCA Laboratories Ltd made by professional analysts.

What are the Revenue projections
for IPCA Laboratories Ltd?

How accurate were the past Revenue estimates
for IPCA Laboratories Ltd?

What are the Net Income projections
for IPCA Laboratories Ltd?

How accurate were the past Net Income estimates
for IPCA Laboratories Ltd?

What are the EPS projections
for IPCA Laboratories Ltd?

How accurate were the past EPS estimates
for IPCA Laboratories Ltd?

What are the EBIT projections
for IPCA Laboratories Ltd?

How accurate were the past EBIT estimates
for IPCA Laboratories Ltd?

Compare the revenue forecasts
for IPCA Laboratories Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of IPCA Laboratories Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of IPCA Laboratories Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of IPCA Laboratories Ltd compared to its peers.

Compare the P/E ratios
of IPCA Laboratories Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing IPCA Laboratories Ltd with its peers.

Analyze the financial leverage
of IPCA Laboratories Ltd compared to its main competitors.

Show all profitability ratios
for IPCA Laboratories Ltd.

Provide ROE
for IPCA Laboratories Ltd.

Provide ROA
for IPCA Laboratories Ltd.

Provide ROIC
for IPCA Laboratories Ltd.

Provide ROCE
for IPCA Laboratories Ltd.

Provide Gross Margin
for IPCA Laboratories Ltd.

Provide Operating Margin
for IPCA Laboratories Ltd.

Provide Net Margin
for IPCA Laboratories Ltd.

Provide FCF Margin
for IPCA Laboratories Ltd.

Show all solvency ratios
for IPCA Laboratories Ltd.

Provide D/E Ratio
for IPCA Laboratories Ltd.

Provide D/A Ratio
for IPCA Laboratories Ltd.

Provide Interest Coverage Ratio
for IPCA Laboratories Ltd.

Provide Altman Z-Score Ratio
for IPCA Laboratories Ltd.

Provide Quick Ratio
for IPCA Laboratories Ltd.

Provide Current Ratio
for IPCA Laboratories Ltd.

Provide Cash Ratio
for IPCA Laboratories Ltd.

What is the historical Revenue growth
over the last 5 years for IPCA Laboratories Ltd?

What is the historical Net Income growth
over the last 5 years for IPCA Laboratories Ltd?

What is the current Free Cash Flow
of IPCA Laboratories Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for IPCA Laboratories Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
IPCA Laboratories Ltd

Current Assets 55.4B
Cash & Short-Term Investments 7.1B
Receivables 19.3B
Other Current Assets 29.1B
Non-Current Assets 55.6B
Long-Term Investments 3B
PP&E 46.6B
Intangibles 2.3B
Other Non-Current Assets 3.6B
Current Liabilities 23.6B
Accounts Payable 7.8B
Accrued Liabilities 949.4m
Short-Term Debt 5.6B
Other Current Liabilities 9.3B
Non-Current Liabilities 24.1B
Long-Term Debt 6.2B
Other Non-Current Liabilities 17.9B
Efficiency

Earnings Waterfall
IPCA Laboratories Ltd

Revenue
82.1B INR
Cost of Revenue
-27B INR
Gross Profit
55.1B INR
Operating Expenses
-44.9B INR
Operating Income
10.2B INR
Other Expenses
-4.4B INR
Net Income
5.8B INR

Free Cash Flow Analysis
IPCA Laboratories Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q2 FY '25, Ipca Laboratories achieved an impressive 14% growth in its domestic business, significantly outpacing the industry average of 8%. The company also noted a strong 22.89% EBITDA margin, surpassing its earlier guidance of 21%. While the export formulation business saw a 15% increase, API exports faced a 5% decline. The anticipated consolidated revenue growth for the entire year is now projected at 9-10%. Management highlighted successful market share gains, with notable strength in both acute and chronic segments. The focus remains on leveraging synergies from the integration with Unichem to further enhance profitability.

What is Earnings Call?
Fundamental Scores

IPCALAB Profitability Score
Profitability Due Diligence

IPCA Laboratories Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Free Cash Flow
Positive Revenue Growth Forecast
57/100
Profitability
Score

IPCA Laboratories Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

IPCALAB Solvency Score
Solvency Due Diligence

IPCA Laboratories Ltd's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Short-Term Solvency
Long-Term Solvency
68/100
Solvency
Score

IPCA Laboratories Ltd's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IPCALAB Price Targets Summary
IPCA Laboratories Ltd

Wall Street analysts forecast IPCALAB stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPCALAB is 1 555.97 INR with a low forecast of 960.51 INR and a high forecast of 2 026.5 INR.

Lowest
Price Target
960.51 INR
40% Downside
Average
Price Target
1 555.97 INR
2% Downside
Highest
Price Target
2 026.5 INR
27% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for IPCALAB?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for IPCALAB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

IPCALAB Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

IPCA Laboratories Ltd Logo
IPCA Laboratories Ltd

Country

India

Industry

Pharmaceuticals

Market Cap

403.7B INR

Dividend Yield

0.25%

Description

Ipca Laboratories Ltd. engages in the manufacture, research, and development of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 15,155 full-time employees. The firm is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. The company offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The firm offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The firm has 17 manufacturing units in India manufacturing API’s and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., USA Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.

Contact

MAHARASHTRA
Mumbai
125, Kandivli Industrial Estate, Kandivli (West),
+912262105000
www.ipca.com

IPO

1994-02-23

Employees

15 155

Officers

Executive Chairman
Mr. Premchand Godha A.C. A., B. Com., CA
CEO, MD & Executive Director
Mr. Pranay Premchand Godha
CFO, MD & Executive Director
Mr. Ajit Kumar Bhanwarlal Jain A.C.A., B.Sc.
Compliance Officer, Corporate Counsel & Company Secretary
Mr. Harish Pandurang Kamath
Executive Director
Mr. Prashant Premchand Godha
Vice President of Operations
Mr. Pawan Kothari
Show More
Vice President of Technical
Mr. Vishnu Saran Singh Kushwaha
President of Marketing
Mr. Sunil Ghai
Senior Vice President of Human Resources
Mr. Sameer S. Tamhane
President of R&D - Chemicals
Dr. Ashok Kumar
Show Less

See Also

Discover More
What is the Intrinsic Value of one IPCALAB stock?

The intrinsic value of one IPCALAB stock under the Base Case scenario is 1 210.96 INR.

Is IPCALAB stock undervalued or overvalued?

Compared to the current market price of 1 591.35 INR, IPCA Laboratories Ltd is Overvalued by 24%.

Back to Top